Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice

Behavioural Brain Research

Volumn 223, Issue 1, 2011, Pages 125-134

  Umathe, Sudhir N ^a   Manna, Shyamshree S S ^a   Jain, Nishant S ^b  

^a RTM NAGPUR UNIVERSITY   (India)

^b JL Chaturvedi College of Pharmacy   (India)

Author keywords

AM404; Anandamide; Marble burying behavior; Obsessive compulsive disorder; Serotonin selective reuptake inhibitors; URB597

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FLUOXETINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FORCED SWIMMING TEST; LOCOMOTION; MALE; MARBLE BURYING BEHAVIOR; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARACHIDONIC ACIDS; BENZAMIDES; CARBAMATES; COMPULSIVE BEHAVIOR; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENDOCANNABINOIDS; FLUOXETINE; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES;

EID: 79955968433     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.04.031     Document Type: Article

References (77)

1. Abdel-Fattah A.F., Matsumoto K., el-Hady K.A., Watanabe H. 5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated rats. Pharmacol Biochem Behav 1995, 52:379-384.
2. Abel E. Gradient of alarm substance in the forced swimming test. Physiol Behav 1991, 49:321-323.
3. Abramowitz J.S., Taylor S., McKay D. Obsessive-compulsive disorder. Lancet 2009, 374:491-499.
4. Aso E., Ozaita A., Serra MÀ, Maldonado R. Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype. Eur Neuropsychopharmacol 2011, 21:11-22.
5. Aso E., Renoir T., Mengod G., Ledent C., Hamon M., Maldonado R., et al. Lack of CB1 receptor activity impairs serotonergic negative feedback. J Neurochem 2009, 109:935-944.
6. Badgy G., Graf M., Anheuer Z.E., Modos E.A., Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5 HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001, 4:399-408.
7. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27:11700-11711.
8. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997, 277:1094-1097.
9. Best A.R., Regehr W.G. Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J Neurosci 2008, 28:6508-6515.
10. Bortolato M., Campolongo P., Mangieri R.A., Scattoni M.L., Frau R., Trezza V., et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 2006, 31:2652-2659.
11. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Argüelles O., Duranti A., et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007, 62:1103-1110.
12. Campos A.C., Guimarães F.S. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1517-1521.
13. Casarotto P.C., Gomes F.V., Resstel L.B.M., Guimarães F.S. Cannabidiol inhibitory effect on marble burying behaviour: involvement of CB1 receptors. Behav Pharmacol 2010, 21:353-358.
14. Chaperon F., Soubrie P., Puech A.J., Thiebot M.H. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 1998, 135:324-332.
15. Cryan J.F., Holames A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005, 4:775-790.
16. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000, 483:52-56.
17. Detke M.J., Johnson J., Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 1997, 5:107-112.
18. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
19. Devlin M.G., Christopoulos A. Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 2002, 80:1095-1102.
20. Egashira N., Mishima K., Uchida T., Hasebe N., Nagai H., Mizuki A., et al. Anandamide inhibits the DOI-induced head-twitch response in mice. Psychopharmacology (Berl) 2004, 171:382-389.
21. Eison A.S., Eison M.S. Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:47-62.
22. Fride E. Endocannabinoids in the central nervous system-an overview. Prostaglandins Leukot Essent Fatty Acids 2002, 66:221-233.
23. Gomes F.V., Casarotto P.C., Resstel L.B.M., Guimarães F.S. Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry 2010, 33:1191-1199.
24. Gomes K.S., de Carvalho-Netto E.F., Monte K.C., Acco B., Nogueira P.J., Nunes-de-Souza R.L. Contrasting effects of acute and chronic treatment with imipramine and fluoxetine on inhibitory avoidance and escape responses in mice exposed to the elevated T-maze. Brain Res Bull 2009, 78:323-327.
25. Gyertyan I. Analysis of the marble burying response, marbles serve to measure digging rather than evoke burying. Behav Pharmacol 1995, 6:24-31.
26. Haller J., Varga B., Ledent C., Freund T.F. CB1 cannabinoid receptor mediates anxiolytic effects: covergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004, 15:299-304.
27. Häring M., Marsicano G., Lutz B., Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 2007, 146:1212-1219.
28. Harrold J.A., Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating?. Br J Nutr 2003, 90:729-734.
29. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
30. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
31. Hermann H., Marsicano G., Lutz B. Coexpression of cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002, 109:451-460.
32. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008, 106:2322-2336.
33. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15:593-599.
34. Hodge J., Bow J.P., Plyler K.S., Vemuri V.K., Wisniecki A., Salamone J.D., et al. The cannabinoid CB1 receptor inverse agonist AM251 and antagonist AM 4113 produce similar effects on the behavioral satiety sequence in rats. Behav Brain Res 2008, 193:298-305.
35. Hounie A.G., do Rosario-Campos M.C., Diniz J.B., Shavitt R.G., Ferrao Y.A., Lopes A.C., et al. Obsessive-compulsive disorder in Tourette syndrome. Adv Neurol 2006, 99:22-38.
36. Hungund B.L., Vinod K.Y., Kassir S.A., Basavarajappa B.S., Yalamanchili R., Cooper T.B., et al. Upregulation of CB1 receptors and agonist-stimulated [35S] GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004, 9:184-190.
37. Ichimaru Y., Egawa T., Sawa A. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 1995, 68:65-70.
38. Joel D. Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:374-388.
39. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003, 9:76-81.
40. La Rana G., Russo R., Campolongo P., Bortolato M., Mangieri R.A., Cuomo V. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide. J Pharmacol Exp Ther 2006, 317:1365-1371.
41. Lau T., Schloss P. The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons. Eur J Pharmacol 2008, 578:137-141.
42. Lisboa S.F., Resstel L.B.M., Aguiar D.C., Guimarães F.S. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 2008, 593:73-78.
43. Londei T., Valentini A.M., Leone V.G. Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 1998, 94:249-254.
44. Marinelli S., Pascucci T., Bernardi G., Puglisi-Allegra S., Mercuri N.B. Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology 2005, 30:864-870.
45. Mato S., Aso E., Castro E., Martin M., Valverde O., Maldonado R., et al. CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J Neurochem 2007, 103:2111-2120.
46. McLaughlin R.J., Hill M.N., Morrish A.C., Gorzalka B.B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav Pharmacol 2007, 18:431-438.
47. McTavish D., Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive-compulsive disorder and panic disorder. Drugs 1990, 39:136-153.
48. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N., Schatz A., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
49. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34:593-606.
50. Millan M.J., Girardon S., Mullot J., Brocco M., Dekeyne A. Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 NK1 receptor antagonists. Neuropharmacology 2002, 42:677-684.
51. Mitchell V.A., Greenwood R., Jayamanne A., Vaughan C.W. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin Exp Pharmacol Physiol 2007, 34:1186-1190.
52. Muller-Vahl K.R., Schneider U., Koblenz A., Jobges M., Kolbe H., Daldrup T., et al. Treatment of Tourette's syndrome with delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002, 35:57-61.
53. Murillo-Rodriguez E., Blanco-Centurion C., Sanchez C., Piomelli D., Shiromani P.J. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep 2003, 26:943-947.
54. Nicolas L.B., Kolb Y., Prinssen E.P. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol 2006, 547:106-115.
55. Njung'e K., Handley S.L. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 1991, 104:105-112.
56. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991, 38:63-67.
57. Oliva J.M., Urigüen L., Pérez-Rial S., Ortiz S., Palomo T., Manzanares J. Chronic treatment with fluoxetine produced time related alterations in opioid, cannabinoid and tyrosine hydroxylase gene expression in selected regions of the rat brain. Eur Neuropsychopharmacol 2003, 13:S245-S246.
58. Overbeek T., Schruers K., Vermetten E., Griez E. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry 2002, 63:1106-1112.
59. Overbury AL, Marsden CA, Kendall DA. Effect of modification of 5-HT metabolism on cannabinoid induced behaviour and receptor function. In: 13th Annual Symposium on the Cannabinoids, 2003, p. 98.
60. Owens M.J., Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994, 40:288-295.
61. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 2006, 111:114-144.
62. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005, 76:1307-1321.
63. Piomelli D., Tarzia G., Duranti A., Toniti A., Mor M., Compton T.R., et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006, 12:21-38.
64. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
65. Rawls S.M., Ding Z., Cowan A. Role of TRPV1 and cannabinoid receptors in AM404-evoked hypothermia in rats. Pharmacol Biochem Behav 2006, 83:508-516.
66. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., et al. Structure-activity relationship for the endogenous cannabinoid anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 2001, 132:631-640.
67. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003, 140:790-801.
68. Rubino T., Realini N., Castiglioni C., Guidali C., Viganó D., Marras E., et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008, 18:1292-1301.
69. Sánchez C., Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?. Psychopharmacology (Berl) 1997, 129:197-205.
70. Santucci V., Storme J.J., Soubrié P., Le Fur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 1996, 58. PL103 10.
71. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001, 22:565-572.
72. Simansky K.J. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 1996, 73:37-42.
73. Slattery D.A., Desrayaud S., Cryan J.F. GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. J Pharmacol Exp Ther 2005, 312:290-296.
74. Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998, 59:347-352.
75. Umathe S.N., Bhutada P.S., Jain N.S., Shukla N.R., Mundhada Y.R., Dixit P.V. Gonadotropin releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice. Neuropeptides 2008, 42:399-410.
76. Umathe S.N., Vaghasiya J.M., Jain N.S., Dixit P.V. Neurosteroids modulate compulsive and persistent behavior in rodents: Implications for obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1161-1166.
77. Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005, 81:331-342.